The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
 
Morten Nielsen
Research Funding - Lytix Biopharma
 
Tine Monberg
No Relationships to Disclose
 
Benedetta Albieri
No Relationships to Disclose
 
Vibeke Sundvold
Employment - Lytix Biopharma
Honoraria - Lytix Biopharma
Research Funding - Lytix Biopharma
Patents, Royalties, Other Intellectual Property - Lytix Biopharma (Inst)
 
Oystein Rekdal
Employment - Lytix Biopharma
Stock and Other Ownership Interests - Lytix Biopharma
Honoraria - Lytix Biopharma
Research Funding - Lytix Biopharma
Patents, Royalties, Other Intellectual Property - Lytix Biopharma (Inst)
 
Niels Junker
No Relationships to Disclose
 
Inge Marie Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer